Practice Variations in Managing Infantile Hemangiomas.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
received:
15
06
2023
accepted:
16
08
2023
medline:
30
10
2023
pubmed:
26
9
2023
entrez:
26
9
2023
Statut:
ppublish
Résumé
Infantile hemangioma (IH) is the most common benign tumor of infancy. For children with IH who require treatment, propranolol and other beta blockers have been shown to be safe and effective. Although consensus guidelines for managing IH have been published, anecdotal experience suggests that there remain variations in management. This study was performed to document these variations amongst providers and to identify areas for future research. We conducted an Internet-based survey of clinicians who treat patients with IH. Hypothetical cases and management scenarios were presented. Twenty-nine respondents participated in the survey. Most respondents use generic propranolol in infants with growing IH of the head and neck, with a goal dose of 2 mg/kg/d, until ~1 year of age. A variety of management strategies were documented including which patients should be treated, optimal dose and duration of therapy, how patients should be monitored, which patients should get additional workup, how propranolol should best be discontinued, and how often to see patients in follow-up. This study demonstrates wide practice variations in managing patients with IH. Further research is indicated to address these variations and develop additional/updated evidence-based guidelines.
Identifiants
pubmed: 37749794
doi: 10.1097/MPH.0000000000002759
pii: 00043426-202311000-00004
doi:
Substances chimiques
Propranolol
9Y8NXQ24VQ
Adrenergic beta-Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
452-460Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390:85–94.
Pahl KS, McLean TW. Infantile hemangioma: a current review. J Pediatr Hematol Oncol. 2022;44:31–39.
Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–2651.
Aly MM, Hamza AF, Abdel Kader HM, et al. Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. Eur J Pediatr. 2015;174:1503–1509.
Darrow DH, Greene AK, Mancini AJ, et al. Diagnosis and management of infantile hemangioma. Pediatrics. 2015;136:e1060–e1104.
Hoeger PH, Harper JI, Baselga E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174:855–865.
Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128:e259–e266.
Leaute-Labreze C, Boccara O, Degrugillier-Chopinet C, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics. 2016;138:e20160353.
Leaute-Labreze C, Voisard JJ, Moore N. Oral propranolol for infantile hemangioma. N Engl J Med. 2015;373:284–285.
Tian Y, Xu DP, Tong S, et al. Oral propranolol for the treatment of infantile hemangiomas in the post-proliferative phase: a-single center retrospective study of 31 cases. J Oral Maxillofac Surg. 2016;74:1623–1629.
Baselga E, Dembowska-Baginska B, Przewratil P, et al. Efficacy of propranolol between 6 and 12 months of age in high-risk infantile hemangioma. Pediatrics. 2018;142:e20173866.
Droitcourt C, Kerbrat S, Rault C, et al. Safety of oral propranolol for infantile hemangioma. Pediatrics. 2018;141:599–607.
Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131:128–140.
Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143:e20183475.
Leaute-Labreze C, Baselga Torres E, Weibel L, et al. The infantile hemangioma referral score: a validated tool for physicians. Pediatrics. 2020;145:e20191628.
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
Martin K, Blei F, Chamlin SL, et al. Propranolol treatme nt of infantile hemangiomas: anticipatory guidance for parents and caretakers. Pediatr Dermatol. 2013;30:155–159.
Chen T, Gudipudi R, Nguyen SA, et al. Should propranolol remain the gold standard for treatment of infantile hemangioma? A systematic review and meta-analysis of propranolol versus atenolol. Ann Otol Rhinol Laryngol. 2023;132:332–40.
Pattanshetti SA, Mahalmani VM, Sarma P, et al. Oral atenolol versus propranolol in the treatment of infantile hemangioma: a systematic review and meta-analysis. J Indian Assoc Pediatr Surg. 2022;27:279–86.
Pope E, Lara-Corrales I, Sibbald C, et al. Noninferiority and safety of nadolol vs propranolol in infants with infantile hemangioma: a randomized clinical trial. JAMA Pediatr. 2022;176:34–41.
Moehrle M, Léauté-Labrèze C, Schmidt V, et al. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol. 2013;30:245–249.
Huang AH, Mannschreck D, Aggarwal P, et al. Retrospective case series of increased oral propranolol dosage for infantile hemangiomas. Pediatr Dermatol. 2020;37:1057–1062.
Yang H, Hu DL, Shu Q, et al. Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies. World J Pediatr. 2019;15:546–558.
Giachetti A, Díaz MS, Boggio P, et al. Early propranolol treatment of infantile hemangiomas improves outcome. An Bras Dermatol. 2023;98:310–315.
Léauté-Labrèze C, Frieden I, Delarue A. Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate. Pediatr Dermatol. 2023;40:261–264.
Gatts JE, Rush MC, Check JF, et al. Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age. Pediatr Dermatol. 2022;39:389–393.
Shah SD, Baselga E, McCuaig C, et al. Rebound growth of infantile hemangiomas after propranolol therapy. Pediatrics. 2016;137:e20151754.
Streicher JL, Riley EB, Castelo-Soccio LA. Reevaluating the need for electrocardiograms prior to initiation of treatment with propranolol for infantile hemangiomas. JAMA Pediatr. 2016;170:906–907.
Horii KA, Drolet BA, Frieden IJ, et al. Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas. Pediatr Dermatol. 2011;28:245–253.
Mahon C, McHugh K, Alband N, et al. Routine liver ultrasound screening does not alter clinical management in a cohort study of multiple cutaneous infantile haemangioma. Br J Dermatol. 2021;184:340–341.
Chang L, Ye X, Qiu Y, et al. is propranolol safe and effective for outpatient use for infantile hemangioma? A prospective study of 679 cases from one center in China. Ann Plast Surg. 2016;76:559–563.
Frieden IJ, Püttgen KB, Drolet BA, et al. Management of infantile hemangiomas during the COVID pandemic. Pediatr Dermatol. 2020;37:412–418.
Smithson SL, Rademaker M, Adams S, et al. Consensus statement for the treatment of infantile haemangiomas with propranolol. Australas J Dermatol. 2017;58:155–159.
Solman L, Glover M, Beattie PE, et al. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines. Br J Dermatol. 2018;179:582–589.
Chang L, Gu Y, Yu Z, et al. When to stop propranolol for infantile hemangioma. Sci Rep. 2017;7:43292.
Fernández Faith E, Shah S, Witman PM, et al. Clinical features, prognostic factors, and treatment interventions for ulceration in patients with infantile hemangioma. JAMA Dermatol. 2021;157:566–572.